Angioplasty Balloons Market Size, Share, Growth, and Industry Analysis, By Type (Scoring Balloon Catheters, Conventional Catheters, DEB Catheters, Cutting Balloon Catheters) By Application (Ambulatory Surgery Centers (ASCs), Hospitals, Catheterization Laboratories (Cath Lab)) and Regional Insights and Forecast to 2034

•   
•   
  

  Request a Free sample to learn more about this report

    

ANGIOPLASTY BALLOONS MARKET OVERVIEW

The global angioplasty balloons market size was USD 2.09 billion in 2025 and is projected to reach 2.41 billion by 2034, exhibiting a CAGR of 1.6% during the forecast period.

The global angioplasty balloons market offers the balloons and balloon catheters which are used to dilate the constrained coronary and peripheral arteries during percutaneous transluminal angioplasty and other procedures; it is at the heart of interventional cardiology and peripheral vascular care and involve a range of balloons, simple compliant/non-compliant balloons to more complex scoring, cutting and drug-coated/drug-eluting balloons to treat restenosis and calcified lesions. Growth is driven by increased cardiovascular disease prevalence worldwide, increasing minimal invasive procedure utilization, ageing population with increasing atherosclerotic burden, and continued utilization of endovascular procedures as an alternative or/and replacement surgery in selected indications. Geographic demand Geographic demand is supported by a well-advanced procedural volume in North America and Western Europe and Asia-Pacific is rapidly expanding due to increased healthcare infrastructure, higher screening and diagnosis rates, and increased adoption of interventional cardiology procedures. This is enabled by innovation in coating technologies (drug delivery), plaque-modification adjuncts (scoring/cutting balloons, intravascular lithotripsy) and the deliverability of the devices themselves, with adoption determined by the reimbursement and hospital investment patterns. A number of industry reports indicate the global market to be currently estimated at the low-mid single-digit billions (USD) of growths and is projected to stabilize in the high single-digit billions (USD) of growths with the increasing sophistication in the devices used and the consistent clinical evidence of drug-coated balloons and other plaque modification devices.

COVID-19 IMPACT

Angioplasty Balloons Market Had a Negative Effect Due to Supply Chain Disruption During COVID-19 Pandemic

The global COVID-19 pandemic has been unprecedented and staggering, with the market experiencing lower-than-anticipated demand across all regions compared to pre-pandemic levels. The sudden market growth reflected by the rise in CAGR is attributable to the market’s growth and demand returning to pre-pandemic levels.

The COVID-19 pandemic affected the angioplasty balloons market share in a material way in several ways: in early 2020-2021 most hospitals postponed or cancelled elective and non-urgent interventional cardiology procedures, leading to a sudden and temporary decrease in the volume of procedures and balloon utilization; the drop diminished temporary revenue to balloon manufacturers and the adoption of some newer devices which rely on elective throughput. Supply-chain disruption (part shortages, transport delays), human resource concerns increased lead times and costs within both manufacturer and hospital systems, and capital spending on novel Cath-lab equipment was delayed in some of the systems during pandemic pressures. At the same time, the unwillingness of clinicians and patients to seek treatment of non-emergency cardiovascular complaints reduced the diagnosis and referral to stable coronary disease, which sub-optimized the demand of elective angioplasty devices. Clinical societies and health systems at that time, however, shifted the emphasis to recovery of the delivery of urgent cardiac care and triage protocol were modified, which helped become rebound in the numbers of procedures, but recovery times were region-specific and the backlog effect moved purchasing behavior. The pandemic also enhanced the interest in the technologies and workflow that reduces the duration of the procedure and the stay in the hospital, which, in its turn, were directed to the devices that offer single-stage procedures with effectiveness.

LATEST TRENDS

AI-native and developer-augmentation: The rise of AI-PaaS and platform features that accelerate application building, observability, and agentic workflows Drives Market Growth

One of the most promising new technology trends in the angioplasty balloon business, particularly in the near future, is drug-coated/drug-eluting balloons (DCBs): these combine the mechanical dilation of a balloon with the local delivery of an antiproliferative drug into the vessel wall, to prevent in-stent restenosis and in some cases prevent the addition of a new stent layer. Clinical trials and registry data, over the past few years, have expanded the evidence base of DCBs in coronary in-stent restenosis and in some peripheral arterial disease applications, and regulatory actions, most notably the FDA approval(s) of DCBs and expanded clearances of some DCB devices, have opened broader markets and made significant DCB development and commercial launches a priority by major companies. It is also driving shifting purchasing mix to more valuable therapeutic balloons in markets where reimbursement is available to purchase them, and is encouraging both major and specialized medtech companies alike to invest in DCB pipelines, coats science and delivery optimization to enhance drug transfer and minimize downstream complications. DCBs are poised to be a long-term complement or substitute to repeat stenting in a select group of patients, improving the market of therapeutic balloons as clinicians optimize case selection and procedural best practices, but further head-to-head evidence generation is necessary.

•   
•   
  

  Request a Free sample to learn more about this report

    

ANGIOPLASTY BALLOONS MARKET SEGMENTATION

By Type

Based on type, the global market can be categorized into Scoring Balloon Catheters, Conventional Catheters, DEB Catheters, Cutting Balloon Catheters

• Scoring Balloon Catheters: Scoring balloons contain a scoring element (micro-blades or wires) on the balloon surface to focus force and make controlled micro-incisions in the fibrotic or recalcitrant plaque to enhance luminal expansion at reduced inflation pressures. They are applied in cases where the dilation on the regular balloons is challenging, and may decrease the movement of balloons and injury of vessels. Calcified or fibrotic lesions, and the use of scoring balloons as a supplement to minimize the use of aggressive atherectomy are the most common indications of its use.

• Conventional Catheters: Basic vessel dilation, prefiltration prior to stents placement, and post-dilatation use convention (standard) angioplasty balloons, of which there are compliant and non-compliant. Non-compliant balloons offer predictable expansion at high pressures to be used as a predictability of sizing whereas compliant balloons are used to fit the anatomy of lesions to achieve gentle dilation. They continue to serve as the workhorse in the majority of the coronary and peripheral angioplasty as it is simple and cost-effective.

• DEB Catheters: DEBs provide an antiproliferative drug on the balloon surface to the vessel wall, which is administered during inflation to inhibit neointimal hyperplasia and decrease restenosis without implanting a metal stent. They are finding more applications in in-stent restenosis and selected de-novo lesions and provide a stent-sparing approach with expanding clinical data. The technology needs optimization coating chemistry, and delivery mechanics to attain efficacy of drug transfer.

• Cutting Balloon Catheters: Cutting balloons contain minute longitudinal blades which cut the plaque as it inflates to allow the plaque to be manipulated and fibrotic/recurring lesions to be dilated. They are especially helpful where there is no indication of rotational atherectomy, or as an adjunct to minimize elastic recoil. Barotrauma is minimized over aggressive high-pressure dilation, controlled scoring.

By Application

Based on Application, the global market can be categorized into Ambulatory Surgery Centers (ASCs), Hospitals, Catheterization Laboratories (Cath Lab)

• Ambulatory Surgery Centers (ASCs): ASCs offer an alternative approach to hospital-based interventional cardiology and peripheral procedures (selected) at approximately one-third of the cost and significantly reduced discharge time. ASCs can maximize the throughput of the procedures and move some of the elective angioplasties out of the hospitals, necessitating short-stay device-optimized workflow devices. ASC use with angioplasty is affected by the reimbursement, case selection, and regulatory environment.
• Hospitals: Decomplex coronary and peripheral procedures continue to be predominantly used by hospitals and large tertiary centers; they contain full cath-lab suites and handle cases of high risk and emergencies that demand extensive support. Hospitals contribute the most volumes of devices because of high-procedural throughput and the management of acute coronary syndromes that cannot be managed in less acute environments. Clinical preference, supply contracts, and capital budgeting have an effect on procurement decisions here.

• Laboratories: Cath labs- inside hospitals or dedicated facilities- form the operational center of angioplasty procedures, where product performance (trackability, profile, burst strength) and operator familiarity are the determinants of product choice. A direct facilitator of angioplasty device demand is investment into cath-lab capacity and operator training, and innovations yielding shorter procedure time or complexity are especially important in such an environment.

MARKET DYNAMICS

Market dynamics include driving and restraining factors, opportunities and challenges stating the market conditions.

Driving Factors

Rising cardiovascular disease burden and aging populations Boost the Market

The largest structural factor behind angioplasty balloons market growth is the global trend of atherosclerotic cardiovascular disease with demographic ageing. As a result of rising life expectancy and aging, more patients in need of percutaneous revascularization due to rising prevalence of coronary artery disease (CAD), peripheral artery disease (PAD), and comorbidities (diabetes, hypertension, chronic kidney disease) are on the rise. In many of the emerging markets, systems of detection, screening and referral are being enhanced which are exposing disease previously not being treated and a resultant rise in the volumes of procedure. Moreover, alterations in secondary prevention result in survival of an increased number of patients following a first cardiovascular event and perhaps additional revascularization following restenosis or disease progression. This steady growth in the number of treatable patients assists in providing long-term and predictable demand growth in all product lines, including low-priced conventional balloons versus more costly drug-coated balloons and scoring/cutting balloons, and dictates the geographic investment policy in Cath-lab facilities.

Technological innovation and clinical evidence favoring therapeutic balloons Expand the Market

The value proposition of angioplasty balloons is shifting with investments in balloon technology drug coating, surface engineering, scoring/cutting mechanics, and deliverability. Effectively, drug-coated balloons (DCBs) that can deliver antiproliferative agents during a short inflation can minimize restenosis and provide a stent-sparing alternative in limited indications; recent regulatory approvals and emerging clinical evidence have boosted clinician confidence and payer readiness to reimburse more-expensive therapeutic balloons. In the same vein, the use of scoring and cutting balloons enhances the success of procedural performance with calcified or fibrotic lesions and may lead to a decrease in the use of the supplementary adjunctive devices. As evidence-based guidelines implement these modalities in certain lesion subsets, they are increasingly implemented in hospitals and by interventionalists, to boost average selling prices and establish new premium segments in the balloon market.

Restraining Factor

Price pressure and budget constraints in hospitals and emerging markets Potentially Impede Market Growth

As the clinical need increases, the angioplasty balloon business is experiencing a negative price pressure and acquisition limitations, particularly in cost sensitive hospitals and emerging economies. Most institutions have stringent capital and consumables budgets; they prefer therapies with an apparent cost-benefit or those that are included in an overall supply contract. DCBs or specialized scoring balloons cost more and unless local reimbursement is strong or short-term cost reduction is clearly demonstrated, a slow adoption rate may be the result. The high rivalry among various manufacturers also adds squeeze on margins, as suppliers are induced to give discounts, package contracts, or less-expensive product lines- reducing profitability and not allowing smaller competitors to invest intensively in research and development.

Expansion in Asia-Pacific and low-middle income markets through capacity building and localized offerings Create Opportunity for The Product in The Market

Opportunity

Emerging markets within Asia-Pacific and some of Latin America offer a large growth potential because health systems are developing cath-lab capacity and increasing access to interventional services. Governments and the private health care system are investing in infrastructure, training and screening interventions that enhance the diagnosis and referral of CAD and PAD.

Manufacturers that differentiate product-portfolio to local requirements; with a combination of affordable conventional balloons and specific product introductions of high-end therapeutic models, training and service programs can be able to secure a large market share. Adoption can be speeded up by partnerships, local manufacturing or distribution agreements, and evidence generation in local patient cohorts.

Need for robust head-to-head clinical evidence and guideline integration Could Be a Potential Challenge for Consumers

Challenge

One issue is that most new balloon technologies (e.g., DCBs in some cases of de-novo coronary lesions, scoring/cutting versions) are yet to be supported by substantial, sustained randomized evidence and guideline recommendations to promote mainstream use and preferential reimbursement. Although a few of the indications (such as coronary in-stent restenosis) now have supportive evidence and regulatory approval, other possible applications remain based on registries or smaller studies.

The payers and hospitals are hesitant to pay a premium when there are no visible results or cost-efficiency statistics. High-quality clinical evidence development is both time-intensive and costly, and smaller companies might not be able to afford large studies; this impedes the general adoption of guidelines and slows large-scale adoption even when pilot findings are encouraging.

•   
•   
  Request a Free sample to learn more about this report

    

ANGIOPLASTY BALLOONS MARKET REGIONAL INSIGHTS

• North America

The biggest and most technologically developed angioplasty balloons market is North America and the United States angioplasty balloons market leads due to the large volumes of procedures, end-to-end reimbursement models and rapid-adoption of novel technology. Mature Cath-lab facilities, large interventional cardiologist team, and positive reimbursement of advanced equipment can help in early adoption of drug-coated balloons, scoring/cutting balloons, and plaque-modification adjuncts (where supported by evidence). The scope of clinical use has been expanded by regulatory clearances (e.g. recent FDA clearances of certain DCBs), and acquisitions and mergers of large MedTech companies are altering the competitive landscape and accelerating the rate of the scale of distribution.

• Europe

The angioplasty balloon market in Europe is marked with high standards of clinical standards, wide access to interventional cardiology, as well as regional differences in reimbursement and adoption levels of the interventional cardiology among the member states. The adoption of newer technologies is relatively fast in the Western and Northern European countries when clinical data and economic feasibility are in harmony, whereas the Eastern European markets are more sluggish in their progress because of limited healthcare finances. Evidence dissemination is supported by European regulatory routes (CE marking) and robust clinical networks (major cardiology conferences and registries); further, a robust community interest in minimally invasive procedures encourages the use of therapeutic balloons. National procurement systems and pricing negotiations can generate dynamic uptake patterns - therefore manufacturers usually seek to find local clinical champions and specific health-economic research to achieve adoption.

• Asia

Asia-Pacific is the most rapidly expanding regional market which is driven by high, ageing populations, growing CAD and PAD incidence, growing healthcare infrastructure and growing access to minimally invasive cardiac care. China, India, Japan, South Korea and Southeast Asian markets are highly heterogeneous: Japan and South Korea are technologically developed and early adopters of high-end devices, whereas China and India demonstrate high growth in volumes due to the extended insurance coverage and novel Cath-lab capacity. Price forces are subject to local manufacturers and low-cost imports, and global corporations tend to engage in alliances, localization and specific training to enter those markets.

KEY INDUSTRY PLAYERS

Key Industry Players Shaping the Market Through Innovation and Market Expansion

The angioplasty balloons segment is supplied by large diversified cardiovascular device companies along with specialty interventional companies. The top international players are Boston Scientific, Medtronic, Abbott Laboratories, Johnson and Johnson (including Cordis), B. Braun, Terumo Corporation, BIOTRONIK, Cook Medical and Cardinal Health, all of which offer wide interventional portfolios and channel coverage in hospitals and cath labs. There are also specialty players and innovators like Shockwave Medical (since acquired by J&J), Merit Medical, AngioDynamics, and several regional manufacturers that manufacture niche or advanced products including scoring and cutting balloons, drug-coated balloons, and adjunctive plaque-modification devices, that complement the offerings of the larger companies. Innovation in products (coating technologies, deliverability) competitiveness depends on clinical trials, service and training support, and contract arrangements with hospital systems and group purchasing organizations. Mergers, acquisitions, and alliances have been on the rise: a recent example is extensive consolidation in related cardiovascular technology that has enhanced incumbents in terms of capabilities and reach. Leadership on the market thus relies as much on R and D and clinical demonstration as on global sales and reimbursement infrastructure.

List Of Top Angioplasty Balloons Companies

• Abbott Laboratories (U.S.)
• Boston Scientific (U.S.)
• R. Bard (U.S.)
• Medtronic (U.S.)

KEY INDUSTRY DEVELOPMENT

March 2024: Boston Scientific FDA approval of the AGENT paclitaxel-coated (drug-coated) balloon for treatment of coronary in-stent restenosis.

REPORT COVERAGE

The angioplasty balloons market is an established yet dynamically developing niche of interventional cardiology and peripheral vascular care: established classes of products (compliant/non-compliant conventional balloons) are the ones that support the high procedural volumes sustaining the market, and therapeutic innovations -drug-coated/drug-eluting balloons, scoring and cutting balloons, and synergy with plaque-modification technologies like intravascular lithotripsy are establishing higher-value market segments and redefining clinical practice with specific les Structural drivers of demand include an ageing population in the world and growth in cardiovascular disease prevalence, as well as a geographic pattern that favors North America and Western Europe in value and Asia-Pacific in volume growth. The COVID-19 pandemic led to a temporary but substantial reimbursement in the elective procedure volume and supply chains; recovery has been uneven but it has also generated renewed interest in efficiency-enhancing devices and outpatient pathways (including ASCs). The trio of factors relates to market growth: establishing and sustaining strong comparative clinical evidence (essential to uptake and reimbursement of high-end devices), capacity by manufacturers to negotiate pricing pressure and fund training and service, and expansion opportunities in high-growth emerging markets by using localized commercial strategies. Consolidation (M&A) and partnership models - e.g. large acquisitions in the MedTech sector - will probably persist as firms aim to integrate complementary technology (i.e. plaque modification and therapeutic balloons) and to achieve economies of scale in commercial reach. In sum, the market perspective is moderate-growth and some areas of premiumization: incumbents and targeted innovation with the ability to show clinical utility, cost-efficacy, and local strength will hold the greatest proportions of future value generation.